Abstract

http://ssrn.com/abstract=2395987
 


 



Patent Trolling — Why Bio & Pharmaceuticals Are at Risk


Robin Feldman


University of California Hastings College of the Law

W. Nicholson Price II


Harvard University - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics

February 14, 2014

UC Hastings Research Paper No. 93

Abstract:     
Patent trolls — also known variously as non-practicing entities, patent assertion entities, and patent monetizers — are a top priority on legislative and regulatory reform agendas. In the modern debates, however, the biopharmaceutical industry goes conspicuously unmentioned. Although biopharmaceuticals are paradigmatically centered on patents, conventional wisdom holds that biopharmaceuticals are largely unthreatened by trolls. This article shows that the conventional wisdom is wrong, both theoretically and descriptively. In particular, the article presents a ground-breaking study of the life science holdings of 5 major universities to determine if these might be attractive to monetizers.

This was deliberately a light, rather than an exhaustive, search. Nevertheless, we identified dozens of patents that could be deployed against current industries. These include patents on active ingredients of drugs; methods of treatment; screening methods to identify new drugs; manufacturing methods; dosage forms; and ancillary technologies that could be deployed in a “peddler’s bag” approach. The article describes the types of patents we found, including an example of each type.

In deciding whether to undertake this analysis, we lost sleep over whether the potential for harm outweighed the potential benefit. If reform efforts are not undertaken, our work could do no more than provide a handy road map for those who would follow. However, with scattered anecdotal evidence suggesting that monetization is moving into biopharmaceuticals, life sciences trolling is predictable and in its infancy. If reforms are implemented before the problem proliferates, legislators and regulators could cabin the activity before it becomes deeply entrenched and too much harm occurs.

Number of Pages in PDF File: 40

Keywords: nonpracticing entities, patent trolls, patent assertion entities, pharmaceuticals, patents, biotechnology

JEL Classification: L65, O34

working papers series


Download This Paper

Date posted: February 15, 2014 ; Last revised: March 15, 2014

Suggested Citation

Feldman, Robin and Price, W. Nicholson, Patent Trolling — Why Bio & Pharmaceuticals Are at Risk (February 14, 2014). UC Hastings Research Paper No. 93. Available at SSRN: http://ssrn.com/abstract=2395987 or http://dx.doi.org/10.2139/ssrn.2395987

Contact Information

Robin Feldman
University of California Hastings College of the Law ( email )
200 McAllister Street
San Francisco, CA 94102
United States

William Nicholson Price II (Contact Author)
Harvard University - Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics ( email )
23 Everett Street
Cambridge, MA 02155
United States
Feedback to SSRN


Paper statistics
Abstract Views: 2,369
Downloads: 528
Download Rank: 28,098

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo7 in 0.235 seconds